Three‐month posttreatment prostate‐specific antigen level as a biomarker of treatment response in patients with intermediate‐risk or high‐risk prostate cancer treated with androgen deprivation therapy and radiotherapy
暂无分享,去创建一个
A. D'Amico | James D. Murphy | C. Kane | A. Mundt | J. Einck | A. Bryant | R. McKay | D. Simpson | B. Rose | P. Nguyen | James D. Murphy